Geoffrey Teehan, MD
Nephrology · Wynnewood, PANPI 1558366237
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,867 of the $72,108 with a category attached, or 85.8%. Bayer accounts for 65.2% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2022 at $35,082 and has fallen 93.8% since, to $2,182 in 2025. Among nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 164 payments — averaging $439.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$47K
- Mallinckrodt Enterprises LLC$13K
- Mallinckrodt Hospital Products Inc.$5K
- Otsuka America Pharmaceutical, Inc.$3K
- ANI Pharmaceuticals, Inc.$1K
- Vifor Pharma, Inc.$1K
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,7102%
- Speaking & faculty fees$61,86786%
- Travel & lodging$3,6145%
- Food & beverage$4,8737%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 49 | $47,023 |
| Mallinckrodt Enterprises LLC | 15 | $12,975 |
| Mallinckrodt Hospital Products Inc. | 5 | $4,817 |
| Otsuka America Pharmaceutical, Inc. | 8 | $2,776 |
| ANI Pharmaceuticals, Inc. | 2 | $1,175 |
| Vifor Pharma, Inc. | 19 | $1,011 |
| Analog Devices Inc. | 2 | $585 |
| Amgen | 15 | $320 |
| AstraZeneca(2 entities) | 8 | $252 |
| Boehringer Ingelheim | 8 | $222 |
| Novartis | 6 | $178 |
| Scpharmaceuticals Inc. | 6 | $177 |
| Travere Therapeutics, Inc. | 4 | $127 |
| Novo Nordisk | 4 | $108 |
| Cormedix Inc. | 3 | $89 |
| Calliditas Therapeutics US Inc. | 3 | $84 |
| GSK | 1 | $39 |
| Lilly USA, LLC | 1 | $31 |
| Aurinia Pharma U.S., Inc. | 1 | $30 |
| Akebia Therapeutics Inc | 1 | $26 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Biomerieux Inc | 1 | $23 |
| Fresenius USA Marketing, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$72,108 in reported general payments places this provider in the 95th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 74 | $67,396 |
| KerendiaFinerenone | 45 | $54,292 |
| FarxigaDapagliflozin Propanediol | 43 | $33,316 |
| LokelmaSodium Zirconium Cyclosilicate | 35 | $12,465 |
| Calcitriol | 389 | $7,139 |
| Cinacalcet Hcl | 12 | $1,687 |
| Nifedipine ErNifedipine | 69 | $1,570 |
| Allopurinol | 84 | $1,325 |
| Irbesartan | 58 | $1,216 |
| Amlodipine Besylate | 124 | $1,068 |
| Valsartan | 30 | $1,012 |
| Calcium Acetate | 16 | $707 |
| Lisinopril | 62 | $647 |
| Carvedilol | 56 | $611 |
| Hydralazine Hcl | 29 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $222 | $67,39674 claims |
| BayerKerendia | $47,023 | $54,29245 claims |
| AstraZenecaFarxiga, Lokelma | $252 | $45,78178 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $1,175 | $1,01230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Wynnewood
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
- Katalin SusztakPhiladelphia$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.